The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection.

@article{Colacino1998TheIA,
  title={The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection.},
  author={Joseph M. Colacino and Kirk A. Staschke},
  journal={Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques},
  year={1998},
  volume={50},
  pages={259-322}
}
Hepatitis B virus (HBV) is the leading cause of chronic hepatitis throughout the world. Notwithstanding the availability of a safe and effective vaccine, the world prevalence of HBV has not declined significantly, thus resulting in the need for a selective antiviral agent. HBV is a small, partially double-stranded DNA virus which replicates through an RNA intermediate. Most efforts to develop anti-HBV agents have been targeted to the viral DNA polymerase which possesses reverse transcriptase… CONTINUE READING